SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that the first patients have been dosed in the SURPASS study, a pivotal Phase 2/3 clinical trial evaluating…